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Summary Epilepsy, antiepileptic drugs (AEDs), and the reproductive system have
complex interactions. Fertility is lower in both men and women with epilepsy than in
the general population. Moreover, reproductive endocrine disorders are more com-
mon among patients with epilepsy than among the population in general. These
disorders have been attributed both to epilepsy itself and to AEDs.
The use of the liver enzyme inducing AEDs phenobarbital, phenytoin and carba-
mazepine increases serum sex hormone binding globulin (SHBG) concentrations in
both men and women with epilepsy. Over time the increase in serum SHBG levels leads
to diminished bioactivity of testosterone and estradiol, which may result in dimin-
ished potency in men and menstrual disorders in some women, and, thus, to reduced
fertility.
Valproate (VPA) medication may have effects on serum androgen concentrations
and it reduces serum follicle stimulating hormone levels in men with epilepsy.
However, the clinical significance of the VPA related reproductive endocrine changes
in men is unknown. On the other hand, in women the use of VPA is associated with a
frequent occurrence of reproductive endocrine disorders characterized by polycystic
changes in the ovaries, high serum testosterone concentrations (hyperandrogenism)
andmenstrual disorders. Young womenwith epilepsy seem to be especially vulnerable
to the effects of VPA on serum androgen levels.
The endocrine effects of the new AEDs have not been widely studied. However, it
seems they may offer an alternative if reproductive endocrine problems emerge
during treatment with the older antiepileptic drugs. On the other hand, it seems that
in many cases the reproductive endocrine effects of the AEDs are reversible, if the
medication is discontinued.
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Epilepsy, antiepileptic drugs, and the reproductive
system have complex interactions. Fertility is lower
in both men and women with epilepsy than in
the general population.1—3 Moreover, reproductive. Published by Elsevier Ltd. All rights reserved.
112 J. Isoja¨rviendocrine disorders are more common among
patients with epilepsy than among the population
in general.4—6 These disorders have been attributed
both to epilepsy itself and to antiepileptic drugs
(AEDs). The potential effects of epilepsy on repro-Table 1 Serum sex hormone and SHBG concentrations in va
epilepsy7
Study medication Number of
patients
T SHBG FAI
Isoja¨rvi 1988
CBZ 23 6¼ " #
MacPhee 1988
CBZ 18 6¼ 6¼ NA
PHT 13 6¼ " NA
VPA 10 6¼ 6¼ NA
Isoja¨rvi 1990
CBZ 20 6¼ 6¼ #
PHT 17 " " #
VPA 7 6¼ 6¼ "
Isoja¨rvi 1991
CBZ 21 6¼ " #
Murialdo 1994
CBZ 10 # " NA
PB 18 6¼ " NA
PHT 7 6¼ " NA
Isoja¨rvi 1995
CBZ* 11 6¼ " #
CBZ 14 6¼ " #
PHT 11 " " #
Duncan 1999
CBZ 31 6¼ " #
PHT 21 " " #
VPA 18 6¼ 6¼ 6¼
Ra¨ttya¨ 2001
CBZ 40 6¼ " 6¼
OXC 29 6¼ 6¼ 6¼
VPA 21 6¼ 6¼ 6¼
Ra¨ttya¨ 2001
CBZ 10 6¼ " #
VPA 12 6¼ 6¼ 6¼
Isoja¨rvi 2004
CBZ 15 6¼ 6¼ 6¼
OXC 17 6¼ 6¼ 6¼
VPA 27 6¼ 6¼ 6¼
Herzog 2004
EIAED 36 NA " #a
LTG 18 NA 6¼ 6¼a
T, testosterone; SHBG, sex hormone binding globulin; FAI, free and
CBZ, carbamazepine; PHT, phenytoin; VPA, valproate; PB, pheno
decreased; NA, not available.
a Calculated bioactive testosterone (BAT).ductive endocrine function are reviewed in detail
elsewhere in this journal. However, it is evident that
AEDs may also alter endocrine function in both men
andwomenwith epilepsy and that this alterationmay
lead to clinically significant reproductive endocrinerious studies on men taking different monotherapies for
Free T A E2 Comments, clinical
consequences
6¼ NA 6¼
# 6¼ NA
6¼ 6¼ NA
6¼ 6¼ NA
6¼ NA 6¼
6¼ NA "
6¼ NA "
A 1-year prospective study
6¼ NA #
# 6¼ 6¼
# 6¼ 6¼
# 6¼ "
High SHBG levels associated
with diminished potency,
5-year prospective data*
NA NA NA
NA NA NA
NA NA NA
6¼ 6¼ 6¼
6¼ 6¼ 6¼
6¼ 6¼ 6¼
NA 6¼ 6¼
NA 6¼ 6¼
NA " 6¼
A 3-month prospective study
NA 6¼ 6¼
NA 6¼ 6¼
NA 6¼ NA
NA 6¼ NA
NA " NA
NA NA 6¼
NA NA 6¼
rogen index (100  T/SHBG); A, androstendione; E2, estradiol;
barbital; LTG, lamotrigine ( 6¼) unchanged; (") increased; (#)
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reproductive endocrine effects of AEDs.Reproductive endocrine effects of
antiepileptic drugs in men
It is well known that AEDs may have undesirable
effects on male sexual function. It was already
known in the 1850s, when bromides were introduced
as a treatment for epilepsy, that these salts pro-
duced impotence.7 Later, a randomized drug trial
showed the development of impotence or decreased
libido in 11—22% of patients after starting mono-
therapy with carbamazepine (CBZ), phenytoin
(PHT), phenobarbital or primidone. However, no
endocrine data was obtained in that study.7
The first studies reporting reproductive endo-
crine abnormalities in men taking AEDs and asso-
ciating them in some cases with sexual dysfunction
were published in the 1970s and 1980s. An increase
in serum sex hormone binding globulin (SHBG) levels
and a consequent decrease in bioactive androgens
was a consistent finding. SHBG is synthesized in the
liver, and it binds and regulates the bioactivity of
both testosterone and estradiol in the circulation.
While serum total testosterone levels were elevated
or normal, low levels of serum bioactive androgens
seemed to be associated with diminished sexual
functions. However, in most of these first studies,
the patients were on polytherapy, which in nearly all
cases included different liver enzyme inducing AEDs
(EIAEDs). The specific effects of particular AEDs on
reproductive endocrine function were therefore
difficult to differentiate. Studies on reproductive
endocrine effects of single AEDs in men with epi-
lepsy will be reviewed in the following. These stu-
dies are summarized in Table 1.
Phenobarbital, phenytoin, carbamazepine
After the early studies in men with epilepsy on
polytherapy with EIAEDs additional studies have
shown that all these drugs taken as monotherapy
are also associated with high serum SHBG levels and
a consequent diminution of free androgens available
for the tissues, which may be associated with dimin-
ished sexual function in men. Elevated serum estra-
diol levels have also been reported in men on PHT,
and high estradiol levels were found to be asso-
ciated with sexual dysfunction in some men.7
The reproductive endocrine effects of CBZ in men
with epilepsy appear to be similar to those observed
during PHT medication, except that CBZ has not
been reported to be associated with elevated serum
total testosterone or estradiol concentrations. Manycross-sectional and prospective studies have
reported that an increase in serum SHBG concen-
trations results in decrease in the levels of bioactive
free androgens (free androgen index, FAI).7 Prospec-
tive studies have shown that the use of CBZ is
associated with a progressive increase in serum
levels of SHBG resulting in low free androgen index
(FAI) ratios reflecting decreased serum levels of
free, bioactive testosterone in male patients.8 This
progressive change appears to result in sexual dys-
function in some men with epilepsy after long-term
CBZ treatment. Low serum DHEAS levels have also
been reported in men on PHT or CBZ. DHEAS is a
weak androgen secreted by the adrenal cortex, and
the clinical significance of decreased serum DHEAS
concentrations is unknown. It has been suggested
that the metabolism of hormones and synthesis of
hormone binding globulins is increased during med-
ication with EIAEDs due to liver enzyme induction.
No consistent abnormalities have been found in the
basal or stimulated serum PRL or gonadotropin
levels in men taking phenobarbital, PHT or CBZ
for epilepsy.7
It has been suggested that PHT may reduce
sperm motility. Furthermore, in one study, PHT
medication was associated with reduced semen
volume, spermatozoa concentration and possibly
sperm count. CBZ has also been suggested to
reduce sperm motility. This was first observed in
an in vitro study, and, therefore was a direct effect
of CBZ on sperm cells.7 Just recently, two clinical
studies in men with epilepsy have shown that CBZ is
associated with reduced sperm motility and
increased frequency of morphologically abnormal
sperm.9,10
Valproate
Valproate (VPA) is not an EIAED. However, studies
suggest that in addition to reducing serum gonado-
tropin levels, VPA also increases serum androsten-
dione concentrations in men with epilepsy. The
mechanism by which VPA alters reproductive endo-
crine function in men with epilepsy is unknown. VPA
modifies GABA-ergic neurotransmission and could
alter the secretion of gonadotropins. On the other
hand, a direct effect of VPA on testicular androgen
synthesis is possible.7
Cases of infertility have been reported in male
subjects taking VPA for epilepsy. An in vitro study
suggested that VPA has direct effects on sperm
motility.7 Two recent clinical studies also showed
that VPA may reduce the sperm motility and
increase the frequency of morphologically abnormal
sperm, and be associated with small testicular size
in men with epilepsy.9,10
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Oxcarbazepine (OXC) is a novel AED that structurally
closely resembles CBZ. However, it has a different
metabolic pathway in the liver: instead of oxidation
it is mainly metabolized by reduction and it does not
appear to induce the oxidative P450 enzyme system.
Earlier studies have shown that CBZ induced liver
enzyme induction and associated changes in endo-
crine and metabolic function become normal after
CBZ is replaced with OXC in men with epilepsy.
However, there is evidence that OXC may also
induce liver enzymes when given in higher doses,
and one study reported that it may have effects on
the bioactivity of serum steroids by increasing serum
testosterone and SHBG concentrations when taken
in high doses in men with epilepsy.7 Another recent
clinical study suggested that OXC may be associated
with increased frequency of morphologically abnor-
mal sperm in men with epilepsy.9
Lamotrigine
In a comparison of sexual function and reproductive
hormone levels amongmen with localization related
epilepsy on lamotrigine, enzyme inducing AEDs, and
normal controls, sexual function scores, bioactive
testosterone levels, bioactive testosterone/bioac-
tive estradiol and bioactive testosterone/LH were
significantly lower in the patient group on liver
enzyme inducing AEDs than in men treated with
lamotrigine (LTG) or the control subjects. SHBG
was also significantly higher in the induced group
than in all other groups (Table 1).7
Other new antiepileptic drugs
The hormonal effects of the other new AEDs (felba-
mate, gabapentin, levetiracetam, pregabalin, tia-
gabine, topiramate, vigabatrin) have not been
studied in men with epilepsy.
Reproductive endocrine effects of AEDs in
male subjects with epilepsy during
pubertal development
A recently published study evaluated reproductive
endocrine function in boys and young men taking
CBZ, LTG, OXC, or VPA as monotherapy for epi-
lepsy.11 Patients taking VPA had high serum
androstenedione levels at all pubertal stages. In
prepuberty, their serum androstenedione values
were already approximately fivefold compared
with the values of the control subjects, and they
were elevated in 64% of the VPA treated patients
compared with none of the other patients.Consistent with what has previously been reported
in adult male subjects with epilepsy serum SHBG
levels were increased and serum DHEAS concen-
trations decreased in pubertal patients taking
CBZ. However, the serum levels of these hormones
were not affected in prepuberty. LTG and OXC
were not associated with changes in serum sex
hormone levels in boys and young men with epi-
lepsy.11Reproductive endocrine effects of
antiepileptic drugs in women
A high number of irregular menstrual cycles in
women with epilepsy were reported in the mid
1950s by Laidlaw. Thereafter, reproductive endo-
crine disorders were suggested to be associated with
epilepsy itself rather than with the medication.
However, in the late 1970s and 1980s serum SHBG
levels were reported to be elevated in women taking
EIAEDs for epilepsy, and Margraf and Dreifuss were
the first to report amenorrhea following initiation of
therapy with VPA, indicating a drug-induced effect.7
Studies on the reproductive endocrine effects of
AEDs in women with epilepsy will be reviewed in
the following. The studies are summarized in
Tables 2 and 3.
Phenobarbital, phenytoin, carbamazepine
In 1977 Victor et al. showed that PHT medication
was associated with elevated serum SHBG concen-
trations in women with epilepsy, and this finding was
later confirmed. Low DHEAS levels have also been
reported in women on PHT. The findings of many
cross-sectional and prospective studies on the
reproductive endocrine effects of CBZ in women
with epilepsy are fairly consistent in reporting
increased serum SHBG levels. Similarly to men the
increase in serum levels of SHBG is progressive in
women taking CBZ for epilepsy. The increase in
SHBG serum concentrations results in a decreased
amount of bioactive estradiol, which may be asso-
ciated with menstrual disorders in some women
after long-term treatment. The increase in serum
SHBG levels also results in a reduction of bioactive
testosterone (FAI). This effect of CBZ may theore-
tically be advantageous in women with hyperandro-
genism. Low serum DHEAS levels have also been
reported in women on CBZ. However, the clinical
significance of the decreased serum concentrations
of this weak androgen is unknown. No consistent
abnormalities in basal or stimulated serum gonado-
tropin or PRL levels have been reported in women
taking PHT or CBZ for epilepsy.7
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Table 2 Serum sex hormone and SHBG concentrations in various studies on women taking different monotherapies
for epilepsy7
Study medication Number of
patients
T SHBG FAI Free T A E2 Comments, clinical
consequences
Isoja¨rvi 1990 *1-year prospective data
CBZ* 10 6¼ " # 6¼ NA 6¼
CBZ 13 6¼ " # 6¼ NA 6¼
Isoja¨rvi 1993
CBZ 49 6¼ " NA 6¼ NA 6¼
VPA 23 " 6¼ NA " NA 6¼
Isoja¨rvi 1995 *5-year prospective data,
low estradiol/SHBG ratios
associated with menstrual
disorders
CBZ* 8 6¼ " NA NA NA #
CBZ 24 6¼ " NA NA NA 6¼
Murialdo 1998
CBZ 23 # 6¼ 6¼ NA NA #
PB 21 6¼ 6¼ 6¼ NA NA #
VPA 21 " 6¼ " NA " #
Vainionpa¨a¨ 1999 Prepubertal, pubertal and
postpubertal girls aged
8—18 years
VPA 41 " a 6¼ " a NA NA 6¼
Isoja¨rvi 2001
CBZ 35 6¼ " 6¼ NA NA NA
VPA 37 " " " NA NA NA
Ra¨ttya¨ 2001 A 3-month prospective study
CBZ 7 6¼ " 6¼ NA 6¼ 6¼
VPA 10 " " 6¼ NA " 6¼
Morrell 2003
LTG 119 6¼ NA NA NA 6¼ NA
VPA 103 " NA NA NA " NA
T, testosterone; SHBG, sex hormone binding globulin; FAI, free androgen index (100  T/SHBG); A, androstendione; E2, estradiol;
CBZ, carbamazepine; PHT, phenytoin; VPA, valproate; PB, Phenobarbital. ( 6¼) unchanged; (") increased; (#) decreased; NA, not
available.
a The reproductive endocrine findings were similar in all pubertal phases.Valproate
Reproductive endocrine effects of VPA in women
with epilepsy have not been systematically studied
until the early 1990s. The first report suggesting a
high incidence of menstrual disorders, linked to
obesity, hyperandrogenism and polycystic ovaries,
in women taking VPA for epilepsy was published in
1993.6 Thereafter, many studies on reproductive
endocrine effects of AEDs in women with epilepsy
have been published.7 The results of the studies are
summarized in Tables 2 and 3. A randomized, open-
label prospective study comparing the reproductive
endocrine effects of VPA and LTG was recently
completed and the results of that study will be
discussed later in this review.The cross-sectional study from 1993 is the only
study in this field that included a large hospital-
based patient population. Altogether 238 women
participated in the study.6 The major finding in
the study was that menstrual disorders were com-
mon among women taking VPA monotherapy for
epilepsy (45%), and that they were frequently asso-
ciated with polycystic ovaries (PCO) and/or hyper-
androgenism, which were seen in 9/10 (90%) of the
women on VPA monotherapy who had menstrual
disorders. PCO and hyperandrogenism were espe-
cially common, if VPAmedication was started before
the age of 20. Moreover, the serum mean androgen
levels were increased in women on VPA.6
Later, similar findings were obtained from a
three-centre study conducted in three European
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Table 3 Frequency of menstrual disorders, hyperandrogenism (HA) and polycystic ovaries (PCO) in various studies on
women taking antiepileptic drugs for epilepsy7
Study medication Number
of
patients
Menstrual
disorders
HA
only
PCO PCO
and/or HA +
menstrual
disorders a
Comments, clinical consequences
Isoja¨rvi 1993 The total frequency of menstrual
disorders in the study was 23/120 (19%)
for the CBZ group and 13/29 (45%) for
the VPA group. Women on VPA had
elevated serum testosterone
CBZ 49 43% 0% 22% 14%
VPA 23 43% 17% 43% 39%
Control women 51 16% 0% 18% 14%
Murialdo 1997 63.6% of VPA-treated women had
luteal Pg levels consistent with
impaired ovulation
CBZ 20 20% NA 21% NA
PB 19 5% NA 13% NA
VPA 11 18% NA 0% NA
Polytherapy, VPA+ 16 38% NA 40% NA Hyperandrogenic anovulation observed
in 44% of women on VPA and in 4% of
women on other medications
Polytherapy, VPA 31 24% NA 13% NA
Murialdo 1998 Women on VPA had elevated serum
testosterone and androstendione
levels, and 63.6% of VPA treated
women had luteal Pg levels
consistent with impaired ovulation
CBZ 23 NA NA 18% NA
PB 21 NA NA 10% NA
VPA 21 NA NA 10% NA
Bauer 2000 The ages of the women or dose or
duration of medication in different
treatment groups not given
CBZ 20 35% NA NA 10%
VPA 18 27% NA NA 11%
Polytherapy, VPA+ 16 18% NA NA 0%
Polytherapy, VPA- 20 30% NA NA 0%
Isoja¨rvi 2001 Women on VPA had elevated serum
testosterone levels
CBZ 35 12% 6% 14% 6%
VPA 37 59% 8% 62% 49%
Control subjects 52 15% 2% 17% 6%
Luef 2002
CBZ 53 32% NA 28% NA
VPA 52 23% NA 25% NA
Betts 2003 Results in women not taking oral
contraceptives given for consistency.
Use of oral contraceptives reduced
the frequency of reproductive
endocrine disorders in all groups
CBZ/LTG 37 NA NA 41% 5%
VPA 39 NA NA 59% 33%
Control subjects 27 NA NA 4 23%
CBZ, carbamazepine; PHT, phenytoin; VPA, valproate; PB, phenobarbital; NA, not available.
a PCOS-like condition.
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strual disorders were reported by 59% of women
on VPA as compared to 12% of CBZ-treated women
and 15% of control women. Hyperandrogenism and/
or PCO were detected in 70% of VPA-treated women
as compared to 20% in the CBZ-treated women and
19% among the control women. Moreover, a short-
term (3 months) prospective study in newly diag-
nosed women starting treatment with VPA suggested
that an increase in serum testosterone and andros-
tendione levels can be seen in approximately half of
the women within 3 months after starting VPA.7
Changes in serum androgen levels have been
detected already before and during pubertal devel-
opment in young girls taking VPA for epilepsy.12 The
mean serum testosterone levels and FAI were high in
all pubertal phases in girls on VPA. Moreover, ele-
vated serum testosterone levels were found in 38%
of the prepubertal, 36% of the pubertal, and 57% of
the postpubertal girls, whereas hyperandrogenism
was seen in only 8% of the pubertal and in none of
the pre- or post-pubertal control girls.12 A 5-year
follow-up of these girls was just recently reported.13
Sixty percent of the girls/women who were on VPA
during the follow-up study had polycystic ovary
syndrome (PCOS) as compared to 25% of girls/
women taking other AEDs, 5.5% of girls whose med-
ication had been discontinued, and 8.3% of control
subjects. Interestingly, out of the 15 girls who had
hyperandrogenism while on VPA during pubertal
development, 5/7 (71.4%) of the girls who still
continued VPA at the time of follow-up had
PCOS, as compared to 1/4 (25%) among girls/
women who had been switched to other medication
and 0/4 among girls whose medication had been
discontinued.
Two studies by Murialdo et al. have also reported
high prevalence of menstrual disorders and hyper-
androgenic anovulation in VPA-treated women with
epilepsy.7 However, the study by Bauer et al. did not
show any differences between CBZ- and VPA-treated
women with epilepsy with regard to reproductive
endocrine parameters, but the interpretation of the
results of this study is difficult, because the age of
the patients, the duration of medication, and sei-
zure frequency in the different treatment groups
were not given.7
Four other studies have also addressed the issue
of reproductive endocrine function in women with
epilepsy. Luef et al. reported similar frequency of
menstrual disorders and PCO in women taking either
CBZ or VPA for epilepsy. Morrell et al. studied pre-
dictors of ovulatory failure in 94 women with epi-
lepsy. Of women using VPA currently or within the
preceding 3 years, 38.1% had experienced at least
one anovulatory cycle in contrast to 10.7% of womennot using VPA within the preceding 3 years. More-
over, women with idiopathic generalized epilepsy
receiving VPA were at highest risk for anovulatory
cycles, polycystic-appearing ovaries, elevated body
mass index, and hyperandrogenism. Another recent
study by Morrell et al. reported higher serum tes-
tosterone levels in women taking VPA for epilepsy
than in women taking LTG.7 Finally, the recent study
by Betts et al. found a 30% prevalence of PCOS in
women ever treated with VPA only as compared to
6% in women ever treated with either CBZ or LTG
only or to 14% among healthy control women.14
It has been suggested that obesity and associated
hyperinsulinemia could be implicated in the devel-
opment of PCO and hyperandrogenism in women
taking VPA. However, PCO and hyperandrogenism
were also found in many lean VPA-treated women
without hyperinsulinemia, and hyperandrogenism in
prepubertal, pubertal and postpubertal girls taking
VPA for epilepsy was not associated with hyperinsu-
linemia.7,12 Hence, obesity and elevated serum
insulin levels do not appear to be the main factors
initiating the process leading to hyperandrogenism
and the development of PCO in VPA-treated women.
However, it seems that obesity and related hyper-
insulinemia may exacerbate the VPA-related repro-
ductive endocrine disorders in women with epilepsy.
It seems likely that VPA has a direct effect on ovarian
androgen production, or as an enzyme inhibitor, it
may inhibit the metabolism of sex steroids and
thereby lead to increased serum androgen levels.7
A recent prospective, randomized, open-label,
multicentre 12-month study evaluated the develop-
ment of components of PCOS and PCOS in 13—40-
year-old women with epilepsy initiating VPA or
LTG.15 A post hoc analysis was conducted in women
>2 years post-menarche (177 LTG, 186 VPA) to
exclude the confounding effect of puberty.
Interestingly, in this study the prevalence of PCO
was 45% at baseline supporting the theory that
epilepsy itself may alter reproductive endocrine
milieu in women with epilepsy. The LH/FSH ratio
was elevated in women with PCO, and the PCO
status at baseline predicted development of ovula-
tory dysfunction during VPA treatment further
emphasizing the relevance of the PCO findings in
the untreated women with epilepsy.16
More women in the VPA group than the LTG group
developed hyperandrogenism or ovulatory dysfunc-
tion in both the prospective analysis (54% VPA, 38%
LTG; p = 0.010) and the post hoc analysis (36% VPA,
23% LTG; p = 0.007). Development of hyperandro-
genism or ovulatory dysfunction was more frequent
with VPA than LTG among those initiating treatment
at age <26 years (44% VPA, 23% LTG, p = 0.002) but
was similarly frequent between groups if treatment
118 J. Isoja¨rviwas started at age 26 years (24% valproate, 22%
lamotrigine). The first year of VPA treatment was
associated with a significant increase in serum tes-
tosterone concentrations in young women with epi-
lepsy, and this increase was especially prominent in
women who were younger than 20 years of age when
the medication was started.15
The impact of age on the development of
valproate-related hyperandrogenism in
women with epilepsy
The likelihood of developing components of PCOS
with VPA treatment appears to depend on the age
at which VPA is introduced. In the prospective study
comparing the endocrine effects of VPA and LTG,
women with epilepsy beginning treatment with VPA
at age <26 years were at highest risk for developing
componentsof PCOSwhereas thosewomenbeginning
treatment with VPA at age 26 years had no higher
risk than women with epilepsy receiving LTG. In
addition, the women who started VPA at the younger
age had a prominent increase in serum testosterone
levels. This observation is consistent with the possi-
bility that a direct effect of VPA on ovarian androgen
secretionmay lead to development of components of
PCOS in women with epilepsy and that the younger
ovary may be more vulnerable to this effect.15
Other studies have made similar observations
regarding the particular vulnerability of younger
women. In one cross-sectional investigation, more
than 60% of women with epilepsy receiving VPA
before age 20 had polycystic-appearing ovaries as
determined by transvaginal ovarian ultrasound in
contrast to 27% of women with epilepsy receiving
other antiepileptic drugs.6 In another cross-sec-
tional study, elevation in serum testosterone levels
was found only in women who had started treatment
with valproate prior to age 25.14
Oxcarbazepine
There are not much data on the reproductive endo-
crine effects of OXC in women with epilepsy. No
reproductive endocrine abnormalities were found
during OXC therapy in girls during pubertal devel-
opment.12 Moreover, in the follow-up report of
these girls, no OXC-related endocrine abnormalities
were found.13
In a recently published study CBZ and OXC had
different effects on reproductive endocrine func-
tion in women with epilepsy. Although both drugs
were associated with low serum T concentrations
and low FAI, only OXC was associated with a high
frequency of elevated levels of A and DHEAS and
with an increased prevalence of PCO.17Lamotrigine
Replacement of VPA with LTG resulted in normal-
ization of endocrine function during 1-year follow-
up in women with a previously identified reproduc-
tive endocrine disorder likely related to VPA med-
ication. This suggests that LTG therapy is not
associated with changes in body weight, or in endo-
crine and metabolic functions in women with epi-
lepsy. Consistent with these data, Morrell et al.
reported that women taking LTG for epilepsy had
lower serum testosterone concentrations than
women taking VPA.7 Moreover, Betts et al. found a
low prevalence of PCOS (6%) among women taking
either LTG or CBZ for epilepsy.14 However, these
women were presented as one group, and the num-
ber of women on either drug, or the individual
results for either drug were not given.
Other new antiepileptic drugs
The reproductive endocrine effects of other new
AEDs (e.g. felbamate, gabapentin, levetiracetam,
pregabalin, tiagabine, topiramate, vigabatrin) have
not been systematically studied in women with
epilepsy.Reversibility of the reproductive
endocrine effects of antiepileptic
drugs after discontinuation of the
medication
Several studies have suggested that the reproductive
endocrine effects of AEDs may be reversible, if the
medication isdiscontinued.CBZ induced liver enzyme
induction and associated changes in endocrine and
metabolic function became normal after CBZ was
replaced with OXC in men with epilepsy. In another
prospective study replacement of VPA with LTG
resulted in normalization of endocrine function dur-
ing a 1-year follow-up in 12 women with a previously
identifiedendocrinedisorder (PCOorhyperandrogen-
ism or both) likely to be related to VPA medication.
Serum insulin and testosterone levels returned to
normal in 2 months after VPA was discontinued,
and the levels remained normal thereafter.7
A 5-year follow-up study in young female subjects
with epilepsy was recently reported.13 Sixty percent
of the girls/women who were on VPA during the
follow-up study had PCOS as compared to 5.5% of
girls whose medication had been discontinued.
Interestingly, out of the 15 girls who had hyperan-
drogenism while on VPA during pubertal develop-
ment, 5/7 (71.4%) of the girls who still continued
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0/4 among girls whose medication had been discon-
tinued.13
Another recent study that investigated the rever-
sibility of the effects of AEDs on reproductive endo-
crine function after withdrawal of AEDs also showed
that withdrawal of CBZ led to significant increases in
serum testosterone concentrations and FAI in both
men and women suggesting that at last some of the
CBZ-associated endocrine changes may be reversi-
ble after the medication is discontinued.18Summary and conclusions
It is well established that most of the old AEDs have
effects on reproductive function in patients with
epilepsy. It is probable that epilepsy itself may
modulate the regulation of reproductive endocrine
function in men and women with epilepsy and that
epilepsy may modify the effects that AEDs have on
reproductive function. The underlying mechanisms,
clinical significance and incidence of the AED-
related reproductive changes differ between var-
ious AEDs. However, it is well established that AEDs
with liver enzyme inducing properties decrease the
serum concentrations of bioactive sex steroids,
whereas VPA increases the serum concentrations
of androgens.
It is important to acknowledge that the repro-
ductive effects of AEDs may be different depending
on the age. Young women with epilepsy seem to be
especially vulnerable to the effects of VPA on ovar-
ian function.
The endocrine effects of the new antiepileptic
drugs have not been widely studied. However, it
seems they may offer an alternative if reproductive
endocrine problems emerge during treatment with
the older AEDs. It is encouraging to note that most of
the reproductive effects of the AEDs appear to be
reversible, if the medication is discontinued before
adulthood.
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